Background Image
Previous Page  84 / 89 Next Page
Information
Show Menu
Previous Page 84 / 89 Next Page
Page Background

84

112.

Galiè N, Olschewski H, Oudiz RJ, Torres F,

Frost A, Ghofrani HÁ, et al. Ambrisentan for

the

treatment

of

pulmonary

arterial

hypertension: results of the ambrisentan in

pulmonary arterial hypertension, randomized,

double-blind, placebo-controlled, multicenter,

efficacy (ARIES) study 1 and 2. Circulation

2008;117:3010-9.

113.

Saggar R, Khanna D, Shapiro S, Furst DE,

Maranian P, Clements P, et al. Effect of

ambrisentan treatment on exercise-induced

pulmonary hypertension in systemic sclerosis:

A prospective single-center, open-label pilot

study. Arthritis Rheum 2012;64:4072-7.

114.

Galiè N, Ghofrani HA, Torbicki A, Barst RJ,

Rubin LJ, Badesch D, et al. Sildenafil citrate

therapy for pulmonary arterial hypertension.

N Engl J Med 2005;353:2148-57.

115.

Badesch DB, Hill NS, Burgess G, Rubin LJ,

Barst RJ, Galiè N, et al. Sildenafil for

pulmonary arterial hypertension associated

with connective tissue disease. J Rheumatol

2007;34:2417-22.

116.

Galiè N, Brundage BH, Ghofrani HA, Oudiz

RJ, Simonneau G, Safdar Z, et al. Tadalafil

therapy for pulmonary arterial hypertension.

Circulation 2009;119: 2894-903

117.

DeMarco PJ, Weisman MH, Seibold JR, Furst

DE, Wong WK, Hurwitz EL, et al. Predictors

and outcomes of scleroderma renal crisis: the

high-dose versus low-dose D-penicillamine in